Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 12/20 | 0.51 |
| ▸ | RAF1 | P04049 | 5/20 | 0.48 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | MELK | Q14680 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27823075 | 0.92 | MELK (0.52) | PRKD1RAF1BRAFMELKLMNA | |
| SCHEMBL5523848 | 0.83 | RAF1 (0.52) | RAF1BRAFLMNAFLT3 | |
| SCHEMBL1790198 | 0.83 | RAF1 (0.69) | PRKD1RAF1BRAFMELKFLT3 | |
| SCHEMBL5534704 | 0.74 | MELK (0.47) | PRKD1MELKFLT3 | |
| SCHEMBL1791767 | 0.74 | RAF1 (0.63) | PRKD1RAF1BRAFMELKLMNA | |
| SCHEMBL1081001 | 0.72 | PRKD1 (0.73) | PRKD1MELKFLT3 | |
| SCHEMBL3842420 | 0.72 | PRKD1 (0.43) | PRKD1MELKSMN1; SMN2FLT3 | |
| SCHEMBL3850883 | 0.71 | BRD4 (0.46) | PRKD1MELKSMN1; SMN2FLT3 | |
| SCHEMBL3850586 | 0.70 | RET (0.46) | PRKD1MELKSMN1; SMN2FLT3 | |
| SCHEMBL15104126 | 0.70 | PRKD1 (0.46) | PRKD1MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959516-A | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2011-01-26 | — | — | CN | disclosed |